{"id":"https://openalex.org/W4281737022","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578","title":"Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study.","display_name":"Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281737022","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.e21578","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023064593","display_name":"Danai Dima","orcid":"https://orcid.org/0000-0002-3587-7975","observed_orcids":["https://orcid.org/0000-0002-3587-7975"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danai Dima","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001528618","display_name":"Nerea Lopetegui\u2010Lia","orcid":"https://orcid.org/0000-0002-6207-2371","observed_orcids":["https://orcid.org/0000-0002-6207-2371"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nerea Lopetegui-Lia","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045874642","display_name":"Olisaemeka Ogbue","orcid":"https://orcid.org/0000-0001-9614-6626","observed_orcids":["https://orcid.org/0000-0001-9614-6626"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olisaemeka Ogbue","raw_affiliation_strings":["Cleveland Clinic Foundation, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060403348","display_name":"Bennett Osantowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bennett Osantowski","raw_affiliation_strings":["Cleveland Clinic Foundation, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068041825","display_name":"Ramsha Ahmed","orcid":"https://orcid.org/0000-0003-1758-2708","observed_orcids":["https://orcid.org/0000-0003-1758-2708"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramsha Ahmed","raw_affiliation_strings":["Cleveland Clinic Foundation, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088832172","display_name":"Diana Basali","orcid":"https://orcid.org/0000-0001-6984-9684","observed_orcids":["https://orcid.org/0000-0001-6984-9684"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Basali","raw_affiliation_strings":["Cleveland Clinic Foundation, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049779232","display_name":"Fatimah Chamseddine","orcid":"https://orcid.org/0000-0001-8828-5554","observed_orcids":["https://orcid.org/0000-0001-8828-5554"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fatimah Chamseddine","raw_affiliation_strings":["Cleveland Clinic Foundation, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112168503","display_name":"Donald Matthew Eicher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald Matthew Eicher","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109153053","display_name":"Jung Min Song","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jung Min Song","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087859996","display_name":"Brian Gastman","orcid":"https://orcid.org/0000-0003-2691-3409","observed_orcids":["https://orcid.org/0000-0003-2691-3409"]},"institutions":[{"id":"https://openalex.org/I36373038","display_name":"Cleveland Clinic Lerner College of Medicine","ror":"https://ror.org/02x4b0932","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750","https://openalex.org/I36373038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Gastman","raw_affiliation_strings":["Cleveland Clinic Lerner College of Medicine, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Lerner College of Medicine, Cleveland, OH;","institution_ids":["https://openalex.org/I36373038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043305392","display_name":"Lucy Boyce Kennedy","orcid":"https://orcid.org/0000-0001-6644-8922","observed_orcids":["https://orcid.org/0000-0001-6644-8922"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucy Boyce Kennedy","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057402683","display_name":"Pauline Funchain","orcid":"https://orcid.org/0000-0002-7568-8626","observed_orcids":["https://orcid.org/0000-0002-7568-8626"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pauline Funchain","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"e21578","last_page":"e21578"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.8579000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.8579000234603882,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0731000006198883,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.05999999865889549,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/stage-iii-melanoma","display_name":"stage III melanoma","score":0.9470000267028809},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.9639999866485596},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9779999852180481},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/dabrafenib-and-trametinib","display_name":"dabrafenib/trametinib","score":0.9610000252723694},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.968999981880188},{"id":"https://openalex.org/keywords/distant-metastasis-free-survival","display_name":"distant metastasis-free survival","score":0.9700000286102295},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9950000047683716},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.8080000281333923},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8090000152587891},{"id":"https://openalex.org/keywords/local-recurrence","display_name":"local recurrence","score":0.531000018119812},{"id":"https://openalex.org/keywords/distant-recurrence","display_name":"distant recurrence","score":0.6069999933242798},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.5230000019073486},{"id":"https://openalex.org/keywords/braf-v600d","display_name":"BRAF V600D","score":0.675000011920929}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9587175846099854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6246308088302612},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5650479793548584},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5392654538154602},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4985160827636719},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.4799390435218811},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4698074460029602},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4574649930000305},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.4537144899368286},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.42205536365509033},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.41092780232429504},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3868034780025482},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.30233919620513916},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2850649654865265},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22026842832565308},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.19617784023284912},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.13580253720283508},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.e21578","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e21578","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399900204","https://openalex.org/W4319461672","https://openalex.org/W4417227494","https://openalex.org/W4410818317","https://openalex.org/W4379345116","https://openalex.org/W7163921503","https://openalex.org/W4409253908","https://openalex.org/W4400271888","https://openalex.org/W4409118018","https://openalex.org/W3167068488"],"abstract_inverted_index":{"e21578":[0],"Background:":[1],"Both":[2,376],"immunotherapy":[3],"(IO)":[4],"and":[5,108,130,221,228,246,258,330,338,378,406],"targeted":[6],"therapy":[7,393],"(TT)":[8],"are":[9,50,410],"approved":[10],"as":[11,19,391],"adjuvant":[12],"(Adj)":[13],"treatment":[14,60,188],"for":[15,394],"stage":[16,86,395],"III":[17,87,396],"melanoma,":[18],"they":[20],"have":[21],"proven":[22],"to":[23,32,55,65,74,166,172,191,207,212,234,304,381,412],"significantly":[24],"decrease":[25,383],"disease":[26,173,208,215,384],"recurrence.":[27],"While":[28],"there":[29],"is":[30,47,64],"evidence":[31],"suggest":[33],"overall":[34],"survival":[35,101,106],"(OS)":[36],"benefit":[37],"with":[38,44,84,402],"TT,":[39,151],"data":[40,143],"demonstrating":[41],"OS":[42,109,317,418],"advantage":[43],"Adj":[45,68,75,91,392],"IO":[46,69,92,123,193,203,229,252,269,339,363,379],"lacking.":[48],"There":[49],"no":[51],"prospective":[52],"head-to-head":[53],"trials":[54,401],"date":[56],"comparing":[57],"these":[58],"two":[59],"modalities.":[61],"Our":[62],"aim":[63],"determine":[66,413],"whether":[67],"equally":[70,382],"improves":[71],"outcomes":[72],"compared":[73],"TT.":[76],"Methods:":[77],"We":[78],"retrospectively":[79],"analyzed":[80],"104":[81,119],"patients":[82],"(pts)":[83],"resected":[85],"melanoma":[88],"who":[89,149,179],"received":[90,122,150,180],"or":[93,189,387],"TT":[94,133,162,227,240,267,337,351,377],"from":[95],"1/2016":[96],"-":[97],"12/2021.":[98],"Relapse":[99],"free":[100,105],"(RFS),":[102],"distant":[103],"metastasis":[104],"(DMFS)":[107],"rates":[110],"were":[111,342,353,365],"assessed":[112],"between":[113,308],"the":[114,146,176,195,198,226,239,251,266,309,324,327,333,336,350,362],"2":[115,310],"groups.":[116],"Results:":[117],"Of":[118],"pts,":[120],"78":[121,177],"(91%":[124],"nivolumab,":[125],"7%":[126],"pembrolizumab,":[127],"2%":[128],"other)":[129],"26":[131,147],"pts":[132,148,178,224,243,255,334],"(100%":[134],"dabrafenib/trametinib).":[135],"Median":[136],"follow":[137,404],"up":[138,405],"was":[139,216,271,290,301,318],"21":[140],"months.":[141],"At":[142,323],"cutoff,":[144],"among":[145],"50%":[152,160],"completed":[153,183],"1":[154,184],"year":[155,185],"of":[156,186,197,225,236,265,298,326,332],"planned":[157,187],"therapy,":[158],"whereas":[159,200,249,360],"discontinued":[161,202],"prematurely":[163,204],"(42%":[164],"due":[165,171,206,211],"adverse":[167],"events":[168],"[AEs],":[169],"8%":[170],"relapse).":[174],"Among":[175],"IO,":[181],"70%":[182],"continued":[190],"receive":[192],"at":[194],"end":[196,325],"study,":[199],"30%":[201],"(18%":[205],"relapse,":[209],"12%":[210],"AEs).":[213],"Relapsed":[214],"noted":[217],"in":[218,238,250,320,335,349,361,416],"6/26":[219],"(23%)":[220],"27/78":[222],"(34.6%)":[223],"groups,":[230],"respectively.":[231],"With":[232],"regards":[233],"location":[235],"recurrence,":[237,385],"group":[241,253,352,364],"2/6":[242],"relapsed":[244,256],"locally":[245,257,386],"4/6":[247],"distally,":[248,388],"14/27":[254],"13/27":[259],"distally.":[260],"The":[261,345],"estimated":[262],"median":[263,316],"RFS":[264],"vs":[268],"groups":[270,311],"not":[272,291,303],"reached":[273],"(NA)":[274],"(95%":[275,283],"Cl:":[276],"17":[277,285],"months,":[278,286],"NA)":[279,287],"vs.":[280],"30":[281],"months":[282],"CI:":[284],"respectively,":[288,341],"which":[289],"statistically":[292,306],"significant":[293,307],"(p":[294,312],"=":[295,313],"0.49).":[296],"Comparison":[297],"DMFS":[299],"rate":[300],"found":[302],"be":[305],"0.86).":[314],"Finally,":[315],"NA":[319],"either":[321],"group.":[322],"study":[328],"91%":[329],"90.5%":[331],"arms,":[340],"still":[343],"alive.":[344],"most":[346],"common":[347],"AEs":[348],"fatigue":[354,366],"(23%),":[355,357],"fever":[356],"nausea/vomiting":[358],"(19%),":[359],"(22%),":[367],"hypothyroidism":[368],"(14%),":[369],"diarrhea/colitis":[370],"(10%),":[371],"pruritic":[372],"rash":[373],"(9%).":[374],"Conclusions:":[375],"appear":[380],"when":[389],"given":[390],"melanoma.":[397],"Prospective,":[398],"randomized":[399],"control":[400],"longer":[403],"larger":[407],"sample":[408],"size":[409],"warranted":[411],"any":[414],"difference":[415],"potential":[417],"benefit.[Table:":[419],"see":[420],"text]":[421]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2022-06-13T00:00:00"}